Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1349MR)

This product GTTS-WQ1349MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1349MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ380MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ4331MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ12131MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ4907MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ12485MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ10376MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ8123MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ6729MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS 1024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW